Brief: Lipocine Completes Enrollment Of Lpcn 1148 Phase 2 Study For Decompensated Cirrhosis
19/12/2022 13:09
Lipocine Inc LPCN.O :
* LIPOCINE COMPLETES ENROLLMENT OF LPCN 1148 PHASE 2 STUDY
FOR
DECOMPENSATED CIRRHOSIS
Source text for Eikon: ID:nPn5F8r0Ja
Further company coverage: LPCN.O
Recent news on Lipocine
See all newsUS STOCKS ON THE MOVE-Halozyme, Moderna, Merck
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
U.S. STOCKS ON THE MOVE-Hecla Mining, XPO, Lipocine
Lipocine surges after Canada approves co's testosterone replacement therapy
Brief: Lipocine Announces Health Canada Approval Of Tlando For Testosterone Replacement Therapy